경부 근긴장이상증 - 시장 인사이트, 역학, 시장 예측(2036년)

Key Highlights:

• The Cervical Dystonia Market is projected to increase during the forecast period (2026-2036). This increase is attributed to heightened awareness among healthcare professionals and the general public regarding cervical dystonia, alongside the aging population.
• The Cervical Dystonia diagnosis relies on clinical examination, thorough patient history assessment, and a deep understanding of the disorder. No specific laboratory or imaging test definitively confirms cervical dystonia, as there are no abnormal findings in such tests associated with the condition.
• The current Cervical Dystonia Market is dominated by the use of botulinum toxin injections, oral medications like benzodiazepines, anticholinergics, muscle relaxants, etc. Among the present treatment options, botulinum toxin injections are the gold standard of treatment and capture the maximum market share.
• The US FDA has approved five therapies - DYSPORT (abobotulinumtoxinA), DAXXIFY (daxibotulinumtoxinA), BOTOX (onabotulinumtoxinA), XEOMIN (incobotulinumtoxinA), MYOBLOC (rimabotulinumtoxinB)/NERBLOC, and others for the treatment of cervical dystonia.
• Botulinum toxin injections are recommended as first-line therapy for most patients, as they provide excellent symptom relief with minimal side effects. The effects are temporary, and injections are repeated quarterly for sustained benefit. Moreover, not all patients respond adequately to this therapy, as some may develop resistance to botulinum toxin over time, leading to decreased effectiveness.
• In 2022, the US had the largest Cervical Dystonia Market Size among the 7MM, accounting for approximately USD 222.2 million. This is expected to increase further by 2036.

DelveInsight's "Cervical Dystonia Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of cervical dystonia, historical and forecasted epidemiology, as well as the cervical dystonia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Cervical Dystonia Treatment Market Report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM cervical dystonia market size from 2022 to 2036. The report also covers Cervical Dystonia treatment market practices/algorithms and Cervical Dystonia unmet needs to curate the best opportunities and assess the market's potential.

Key Factors Driving the Cervical Dystonia Market

Rising Cervical Dystonia Prevalence

According to DelveInsight's estimates, in 2022, there were approximately 106K total diagnosed prevalent cases of cervical dystonia in the 7MM. These cases are expected to increase during the study period (2020 -2034).

Dominance & Expansion of Botulinum Toxin (BoNT) Therapies

BoNT-A injections remain the standard of care for focal cervical dystonia; broader adoption, new formulations/brands, and label expansions are the single largest commercial engine for the market. BoNT market growth underpins cervical dystonia market revenue forecasts.

Cervical Dystonia Treatment Market

Dystonia is a complex neurological condition characterized by involuntary muscle contractions that lead to abnormal movements and posture. It is often classified depending on which parts of the body are affected. Such as focal dystonia, segmental dystonia, generalized dystonia, multifocal dystonia, and others. Cervical dystonia, also known as spasmodic torticollis, is the most common form of focal dystonia. It is a rare neurological movement disorder characterized by sustained or intermittent muscle contractions in the neck, resulting in functional impairment, sensory symptoms, muscle spasms, abnormal movements, and posture.

Cervical Dystonia Diagnosis

A diagnosis of cervical dystonia is based on clinical examination, a detailed patient history, and knowledge of the disorder. No specific laboratory or imaging test confirms a diagnosis of cervical dystonia. There are no abnormalities in laboratory or imaging tests. Magnetic resonance imaging (MRI) of the brain is normal, and MRI of the neck does not help with the diagnosis unless compression of the spinal cord is suspected. Electromyography is not indicated unless there are additional signs of nerve irritation.

Cervical Dystonia Treatment

The major Cervical Dystonia treatment options include botulinum toxin injections, oral medications, and, in some cases, surgery. These Cervical Dystonia treatment approaches focus on alleviating symptoms and improving functional abilities in cervical dystonia patients. The US FDA-approved botulinum toxin therapies includes DYSPORT (abobotulinumtoxinA), DAXXIFY (daxibotulinumtoxinA), BOTOX (onabotulinumtoxinA), XEOMIN (incobotulinumtoxinA), and MYOBLOC (rimabotulinumtoxinB). Botulinum toxin is the primary treatment modality for cervical dystonia.

Cervical Dystonia Epidemiology

As the market is derived using a patient-based model, the cervical dystonia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of cervical dystonia, gender-specific diagnosed prevalent cases of cervical dystonia, and type-specific diagnosed prevalent cases of cervical dystonia in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2022 to 2036.

• Among EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases of cervical dystonia which was approximately 22,000 cases, followed by the UK with nearly 8,000 cases, while Spain accounted for the least cases around 2,700 in 2025. These cases are expected to change during the forecast period (2026-2036).
• According to the estimates based on DelveInsight's epidemiology model for cervical dystonia, in EU4 and the UK, the gender-specific cases of cervical dystonia, females accounted for more cases, nearly 30,000, while males accounted for 13,000 cases in 2025. These cases are expected to change during the forecast period (2026-2036).
• In 2025, Japan accounted for approximately 3,500 diagnosed prevalent cases of cervical dystonia. As per DelveInsight's analysis, the diagnosed prevalent cases are expected to increase by 2036.
• As per DelveInsight's epidemiology model, the type specific cervical dystonia includes torticollis, laterocollis, retrocollis, and anterocollis. In 2025, of the total diagnosed cervical dystonia cases, torticollis accounted for the highest number of cases, with nearly 2,500, followed by laterocollis with ~900 cases, retrocollis ~250, and anterocollis ~110 cases in Japan. These cases are expected to change during the forecast period (2026-2036).

Cervical Dystonia Drug Chapters

The drug chapter segment of the cervical dystonia treatment market report encloses a detailed analysis of cervical dystonia-marketed drugs and mid to late-stage (Phase III and Phase II) Cervical Dystonia pipeline drugs. It also helps to understand the cervical dystonia clinical trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest Cervical Dystonia news and press releases.

Cervical Dystonia Marketed Drugs

• DYSPORT (abobotulinumtoxinA): Ipsen

DYSPORT is an injectable form of botulinum toxin type A (BoNT-A), which is isolated and purified from clostridium bacteria producing BoNT-A. The drug is being supplied as a lyophilized powder. It has been approved in the US for the treatment of adults with cervical dystonia and other movement disorders, including blepharospasm, hemifacial spasms, and spasticity affecting the upper and/or lower limbs in adults and children aged 2 years or older. Furthermore, DYSPORT has marketing authorizations in more than 90 countries worldwide. The product is referred to by different names like RELOXIN (US), AZZALURE (EU), ALLUZIENCE (UK), etc in aesthetic markets.

In April 2009, the US FDA approved DYSPORT (abobotulinumtoxinA) for the treatment of cervical dystonia in adults to reduce the severity of abnormal head position and neck pain in both toxin-naive and previously treated patients. In 2011, DYSPORT was approved in Europe for the treatment of cervical dystonia.

• DAXXIFY (daxibotulinumtoxinA): Revance Therapeutics

DAXXIFY (daxibotulinumtoxinA) (formerly known as RT002) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the treatment of cervical dystonia in adults and the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. Moreover, DAXXIFY is powered by Peptide Exchange Technology, Revance's proprietary, synthetic, 35-amino-acid stabilizing excipient, and is developed free of human serum albumin or animal-based components. DAXXIFY is supplied as a lyophilized powder for reconstitution in single-dose 50 U and 100 U vials. The total recommended dose is 40 U per treatment session divided into five equal intramuscular injections of 8 Units each (two injections in each corrugator muscle and one injection in the procerus muscle).

In August 2023, the US FDA approved DAXXIFY (daxibotulinumtoxinA) for the treatment of cervical dystonia in adults.

• BOTOX (onabotulinumtoxin A): AbbVie (Allergan)

BOTOX (onabotulinumtoxinA) is an acetylcholine release inhibitor, and a neuromuscular blocking agent indicated for the treatment of patients with cervical dystonia in adult patients to reduce the severity of abnormal head position and neck pain. It is also being used for other indications, including overactive bladder, urinary incontinence, and prophylaxis of headaches in adult patients with chronic migraine, spasticity, axillary hyperhidrosis, blepharospasm, and strabismus. Botox is marketed by GSK in Japan.

• XEOMIN (incobotulinumtoxin A): Merz Pharmaceutical/Teijin Pharma

XEOMIN (incobotulinumtoxinA) is an acetylcholine release inhibitor, and neuromuscular blocking agent indicated for the treatment of adults with cervical dystonia to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naive and previously treated patients and for blepharospasm in adults previously treated with onabotulinumtoxinA.

IncobotulinumtoxinA is a highly potent active ingredient. It is a purified neurotoxin type A (150kD) free from complex proteins that prevent the release of the neurotransmitter acetylcholine from nerve endings in muscles and salivary glands. This prescription medicine is used intramuscularly to treat increased muscle stiffness, e.g. in the arm or shoulder of adults with upper limb spasticity, or abnormal head position that happens with cervical dystonia (spasmodic torticollis) in adults.

Additionally, XEOMIN is approved for the treatment of upper and lower limb spasticity, blepharospasm, or hypersalivation.

• MYOBLOC/NERBLOC (rimabotulinumtoxinB): Supernus Pharmaceuticals/Eisai

MYOBLOC is an acetylcholine release inhibitor indicated for the Cervical Dystonia treatment to reduce the severity of abnormal head position and neck pain associated with cervical dystonia in adults and the treatment of chronic sialorrhea in adults. The product is referred to as NERBLOC in Japan by Eisai, MYOBLOC in the US market, and NEUROBLOC in the European market.

Cervical Dystonia Emerging Drugs

• ABP-450 (prabotulinumtoxinA): AEON Biopharma

ABP-450 is a prabotulinumtoxinA that inhibits the release of acetylcholine, relieving muscle contraction and spasms associated with many conditions, such as incontinence and cervical dystonia. ABP-450 contains a 900-kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. The active part of the botulinum toxin is the 150-kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins that are believed to help with the function of the active portion of the botulinum toxin. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle.

Additionally, ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name JEUVEAU.

ABP-450 completed a Phase II clinical trial in cervical dystonia and is anticipated to initiate a Phase III clinical trial. Recently the company presented its topline results at the TOXINS 2024 conference. Moreover, the drug is also being investigated in multiple indications, including gastroparesis, posttraumatic stress disorder, and chronic and episodic migraine.

IPN10200: Ipsen

IPN10200 is Ipsen's first-in-class recombinant molecule, engineered to combine the active sequence of botulinum toxin type A with the binding domain of botulinum toxin type B. It is designed to enhance receptor affinity and cellular internalization, resulting in a longer and clinically meaningful duration of effect. The molecule has been optimized to improve safety and efficacy and is currently being evaluated in four Phase II clinical trials across both therapeutic and aesthetic indications. It is currently being evaluated in Phase II clinical trial for cervical dystonia.

Cervical Dystonia Drugs Market Insights

In the 21st century, the gold standard for symptomatic Cervical Dystonia treatment is botulinum toxin injections, which are administered into target neck muscles to cause selective denervation and relaxation of the abnormal neck posture. For cervical dystonia, because the muscles pulling or twisting the neck to one side are overactive, botulinum toxin injections work to calm those specific muscles and allow for the neutral head position by disrupting the nerve and the muscle, thereby weakening the muscle that it is injected into.

It inhibits the release of acetylcholine (ACh) at the neuromuscular junction, thereby blocking neuromuscular conduction and muscle contraction. The normal release of ACh at the neuromuscular junction occurs through the formation of the synaptic fusion complex of ACh vesicles bound to the presynaptic membrane by soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins. SNARE proteins form a trans complex of three proteins, including syntaxin 1, synaptosomal-associated protein 25 (SNAP-25), and synaptobrevin, which mediate the docking and exocytosis of ACh vesicles at the presynaptic nerve terminal. The mechanism of action of the various serotypes of botulinum toxins are similar, as all cleave the SNARE proteins; however, BoNT A, C, and E cleave SNAP-25, and BoNT B, D, F, and G cleave synaptobrevin.

Botulinum toxin injections are recommended as first-line therapy for most patients, as they provide excellent symptom relief with minimal side effects. The effects are temporary, and injections are repeated quarterly for sustained benefit. In the US, five botulinum toxin injections are approved by the US FDA for the treatment of cervical dystonia. Among these, four are type A toxins, Ipsen's DYSPORT (abobotulinumtoxinA), Revance Therapeutics' DAXXIFY (daxibotulinumtoxinA), Merz Pharmaceutical and Teijin Pharma's XEOMIN (incobotulinumtoxinA), and AbbVie's BOTOX (onabotulinumtoxinA), while one type B toxin, Supernus Pharmaceuticals and Eisai's MYOBLOC (rimabotulinumtoxinB).

Cervical Dystonia Market Outlook

The approach to treating cervical dystonia focuses on managing symptoms and is considered optional, with therapy aimed at improving neck alignment, reducing pain, addressing cosmetic concerns, and minimizing treatment-related side effects. While some individuals with mild symptoms may opt not to pursue treatment unless the abnormal head posture or movement significantly impacts their appearance, those experiencing disabling pain or severe neck movements that interfere with daily activities typically require intervention.

Treatment can be both pharmacological and neurosurgical. Pharmacological treatment includes botulinum toxin injections, oral medications like baclofen, benzodiazepine derivatives, analgesics, anticholinergics, and antidopaminergics. In some patients, botulinum toxin injections are not sufficient to control the symptoms, and oral medications may be useful as additional treatment. These include benzodiazepines such as clonazepam, anticholinergics such as trihexyphenidyl, and muscle relaxants such as baclofen. However, useful adjuncts in patients are often of limited benefit due to systemic side effects and relatively modest anti-dystonia effects.

However, none of these are curative therapies and are often associated with side effects. All of these medications can be associated with muscle weakness, somnolence (sleepiness), dizziness, imbalance, and fogginess. In addition, trihexyphenidyl can cause dry mouth, nausea, constipation, urinary retention (inability to urinate), and confusion. Surgical treatments for dystonia refractory to medications and BoNT therapies include deep brain stimulation and selective peripheral denervation. DBS with electrodes placed in the globus pallidus interna has been effective in the treatment of generalized dystonia; however, there have been inconsistent results with the use of DBS for cervical dystonia. DBS is like a pacemaker for the brain and results in non-permanent suppression of a deep part of the brain.

The pipeline is limited, with no major product in development except ABP-450 (prabotulinumtoxinA). Thus, it is anticipated that the cervical dystonia market will largely be driven by the products already in the market, and there is a need to increase disease awareness and improve the efficacy and durability of the current regime to further expand the market in the forecast period (2026-2036).

The current Cervical Dystonia Market Segmentation is based on the therapies prescribed. The Cervical Dystonia Drugs that are being used in the present market include DYSPORT (abobotulinumtoxinA), DAXXIFY (daxibotulinumtoxinA), BOTOX (onabotulinumtoxinA), XEOMIN (incobotulinumtoxinA), and others are included. These are the major segments covered in the forecast model.

Very few Cervical Dystonia Companies are evaluating their lead candidates in different stages of clinical development like ABP-450 (prabotulinumtoxinA) by AEON Biopharma. The market for Cervical Dystonia is expected to experience positive growth.

• The total Cervical Dystonia Market Size in the 7MM was approximately USD 303.4 million in 2022 and is projected to increase during the forecast period (2026-2036).
• The Cervical Dystonia Market Size in the US was approximately USD 222.2 million in 2022, which is anticipated to increase due to the increasing awareness of the disease and the launch of the emerging therapy.
• The total Cervical Dystonia Market Size of EU4 and the UK was calculated to be approximately USD 73.2 million in 2022, which was nearly 24.1% of the total market revenue for the 7MM.
• According to DelveInsight's estimates, among EU4 and the UK, Germany accounted for the highest market with approximately USD 37.1 million in 2022, followed by the UK with approximately USD 13.9 million in the respective year, while Spain accounted for the lowest market in 2022.
• According to DelveInsight's analysis, in the US, among the currently used therapies, the majority of the market share was of BOTOX (onabotulinumtoxinA) with a revenue of approximately USD 135.7 million, in 2022, followed by other therapies.
• In 2022, Japan with a revenue of approximately USD 8.1 million, which was nearly 2.7% of the total market revenue for the 7MM, which is expected to increase significantly by 2036.

Cervical Dystonia Drugs Uptake

This section focuses on the uptake rate of potential Cervical Dystonia drugs expected to be launched in the market during 2022-2036. For example, AEON Biopharma's ABP-450, a prabotulinumtoxinA, which functions by inhibiting the release of acetylcholine, thereby alleviating muscle contraction and spasms commonly observed in various conditions including incontinence and cervical dystonia, is expected to enter the US market in 2027 with a "fast" uptake.

Cervical Dystonia Pipeline Development Activities

The Cervical Dystonia therapeutics market provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes Cervical Dystonia Companies involved in developing targeted therapeutics.

Pipeline development activities

The Cervical Dystonia therapeutics market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Cervical Dystonia emerging therapies.

KOL Views

To keep up with current Cervical Dystonia market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on cervical dystonia evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and Others.

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like Cedars Sinai Medical Center, Los Angeles, US, University of California, San Francisco, US, Massachusetts General Hospital, Boston, US, Hannover Medical School, Hannover, Germany, Sorbonne Universite, Paris, France, Lancaster University, England, UK, and Fukuoka University, Japan were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or cervical dystonia market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the Cervical Dystonia Therapeutics Market and the Cervical Dystonia Unmet Needs.

Physician's View

According to our primary research analysis, despite advancements in the Cervical Dystonia Treatment, significant unmet needs persist in effectively managing the condition. One such challenge lies in the variability of patient responses to existing therapies, particularly botulinum toxin injections, which serve as the primary treatment. Not all patients respond optimally to this intervention, and some may develop resistance over time, necessitating alternative approaches. Additionally, while botulinum toxin injections effectively target muscle contractions, they may not fully address associated non-motor symptoms such as pain, depression, and impaired quality of life. Furthermore, there remains a lack of standardized protocols for long-term management, leading to uncertainty regarding the optimal treatment duration and frequency.

According to a KOL in the US, the disease is often misdiagnosed, and because cervical dystonia is not as well-known as many other neurologic conditions, the journey to a diagnosis can be long. Cervical dystonia symptoms can mimic neck sprain, slipped disk in the neck, tremor, and Parkinson's disease. We believe raising awareness about cervical dystonia and its symptoms among healthcare providers and the general public can contribute to early detection and appropriate disease management. As per another KOL, management typically involves a combination of treatments such as botulinum toxin injections, oral medications, physical therapy, and in some cases, surgery. Despite this, they are not very effective in treating cervical dystonia. Therefore, we need a new generation of therapies that is curative or can help slow the progression of the disease.

Another KOL found that the BoNT injections are typically administered every 3-4 months to maintain symptom control in cervical dystonia. For some people, having to get injections regularly can be a hassle. For others, the cost of BoNT injections can also be a major factor, particularly if there are out-of-pocket costs or if insurance does not cover the full cost.

Qualitative Analysis

We perform Qualitative and Cervical Dystonia Therapeutics Market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving Cervical Dystonia treatment landscape.

Cervical Dystonia Therapeutics Market Access and Reimbursement

The high cost of therapies for the Cervical Dystonia Treatment is a major factor restraining the growth of the drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment. The reimbursement challenges related to medical care and treatment for individuals with cervical dystonia can be significant as it often requires specialized medical attention, covering the costs of diagnosis, Cervical Dystonia treatment, and ongoing care. Health insurance plans may not fully cover limited coverage of some medical treatments, and therapies specific to cervical dystonia. This can result in high out-of-pocket expenses for families seeking the best care for their loved ones. Moreover, it requires specialized care from healthcare providers with expertise. Finding and accessing such specialists may be challenging, and the associated costs may not always be fully reimbursed by insurance.

The Cervical Dystonia Therapeutics Market Report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenarios, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Cervical Dystonia Treatment Market Report Scope

• The Cervical Dystonia treatment market report covers a segment of key events, an executive summary, and a descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the Cervical Dystonia epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and Cervical Dystonia treatment guidelines have been provided.
• Additionally, an all-inclusive account of the current and Cervical Dystonia emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current Cervical Dystonia treatment market landscape.
• A detailed review of cervical dystonia, historical and forecasted Cervical Dystonia market size, Cervical Dystonia market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The patient-based Cervical Dystonia Market Forecasting report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM cervical dystonia treatment market.

Cervical Dystonia Treatment Market Report Insights

• Patient-based Cervical Dystonia Market Forecasting
• Therapeutic Approaches
• Cervical Dystonia Pipeline Analysis
• Cervical Dystonia Market Size
• Cervical Dystonia Market Trends
• Existing and Future Cervical Dystonia Treatment Market Opportunity

Cervical Dystonia Treatment Market Report Key Strengths

• 11 years Cervical Dystonia Market Forecast
• The 7MM Coverage
• Cervical Dystonia Epidemiology Segmentation
• Key Cross Competition
• Attribute analysis

Key Cervical Dystonia Treatment Market Assumptions

• Cervical Dystonia Market Forecast Report Assessment
• Current Cervical Dystonia Treatment Market Practices
• Cervical Dystonia Unmet Needs
• Cervical Dystonia Pipeline Product Profiles
• Cervical Dystonia Treatment Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

Cervical Dystonia Treatment Market Insights

• What was the total Cervical Dystonia market size, the Cervical Dystonia market size by therapies, and market share (%) distribution in 2022, and what would it look like by 2036? What are the contributing factors for this growth?
• How will DYSPORT, DAXXIFY, and others affect the treatment paradigm of cervical dystonia?
• How will ABP-450 (prabotulinumtoxinA) compete with upcoming products and marketed therapies?
• Which Cervical Dystonia drug is going to be the largest contributor by 2036?
• What are the pricing variations among different geographies for approved and marketed therapies?
• How would future opportunities affect the Cervical Dystonia market dynamics and subsequent analysis of the associated trends?

Cervical Dystonia Epidemiology Insights

• What are the disease risks, burdens, and Cervical Dystonia unmet needs? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Cervical Dystonia?
• What is the historical and forecasted cervical dystonia patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Out of the countries mentioned above, which country would have the highest diagnosed prevalent cervical dystonia population during the forecast period (2026-2036)?
• What are the contributing factors to the evolving trends in cervical dystonia prevalence?

Current Cervical Dystonia Treatment Market Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the Cervical Dystonia treatment? What are the current clinical and treatment guidelines for treating cervical dystonia?
• How many Cervical Dystonia companies are developing therapies for the treatment?
• How many Cervical Dystonia emerging therapies are in the mid-stage and late stage of development for treating cervical dystonia?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What is the cost burden of current Cervical Dystonia treatment on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the accessibility issues of approved therapy in the US?
• What is the 7MM historical and forecasted Cervical Dystonia market?

Reasons to Buy:

• The patient-based Cervical Dystonia market forecasting report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the cervical dystonia drugs market.
• Insights on patient burden/disease Cervical Dystonia prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Cervical Dystonia drugs market opportunities in varying geographies and the growth potential over the coming years.
• The distribution of historical and current patient share is based on real-world prescription data in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• Identifying upcoming solid Cervical Dystonia companies in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies for cervical dystonia, barriers to accessibility of approved therapy, and patient assistance programs.
• To understand Key Opinion Cervical Dystonia Companies perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the Cervical Dystonia unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Cervical Dystonia Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Cervical Dystonia in 2022
• 3.2. Market Share (%) Distribution of Cervical Dystonia in 2036

4. Methodology of Cervical Dystonia Epidemiology and Market

5. Executive Summary of Cervical Dystonia

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction to Cervical Dystonia
• 7.2. Sign and Symptoms
• 7.3. Risk Factors
• 7.4. Subtypes of Cervical Dystonia
• 7.5. Pathophysiology
• 7.6. Diagnosis of Cervical Dystonia
  • 7.6.1. Diagnostic Algorithm
• 7.7. Treatment and Management for Cervical Dystonia
  • 7.7.1. Pharmacological Treatment
  • 7.7.2. Non-pharmacological Treatment
  • 7.7.3. Treatment Algorithm
    • 7.7.3.1. Treatment regime in the US
    • 7.7.3.2. Practical guidance for cervical dystonia management involving treatment of botulinum toxin
• 7.8. Treatment Guidelines
  • 7.8.1. American Academy of Neurology (AAN) Clinical Practice Guidelines (2016)
  • 7.8.2. European Federation of the Neurological Societies Practice (EFNS) Guidelines (2011)
  • 7.8.3. American Family Physician (2017)

8. Patient Journey

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: The 7MM
  • 9.2.1. Diagnosed Prevalent Cases of Cervical Dystonia
  • 9.2.2. Gender-specific Cases of Cervical Dystonia
  • 9.2.3. Type-specific Cases of Cervical Dystonia
• 9.3. Total Diagnosed Prevalent Cases of Cervical Dystonia in the 7MM
• 9.4. The US
  • 9.4.1. Total Diagnosed Prevalent Cases of Cervical Dystonia in the US
  • 9.4.2. Gender-specific Diagnosed Prevalent Cases of Cervical Dystonia in the US
  • 9.4.3. Type-specific Diagnosed Prevalent Cases of Cervical Dystonia in the US
• 9.5. EU4 and the UK
  • 9.5.1. Total Diagnosed Prevalent Cases of Cervical Dystonia in EU4 and the UK
  • 9.5.2. Gender-specific Diagnosed Prevalent Cases of Cervical Dystonia in EU4 and the UK
  • 9.5.3. Type-specific Diagnosed Prevalent Cases of Cervical Dystonia in EU4 and the UK
• 9.6. Japan
  • 9.6.1. Total Diagnosed Prevalent Cases of Cervical Dystonia in Japan
  • 9.6.2. Gender-specific Diagnosed Prevalent Cases of Cervical Dystonia in Japan
  • 9.6.3. Type-specific Diagnosed Prevalent Cases of Cervical Dystonia in Japan

10. Marketed Drugs

• 10.1. Key Cross Competition
• 10.2. DYSPORT (abobotulinumtoxinA): Ipsen
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Development Activities
  • 10.2.4. Clinical Development
  • 10.2.5. Clinical Trials Information
  • 10.2.6. Safety and Efficacy
  • 10.2.7. Product Profile
• 10.3. DAXXIFY (daxibotulinumtoxinA): Revance Therapeutics
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Development Activities
  • 10.3.4. Clinical Development
  • 10.3.5. Clinical Trials Information
  • 10.3.6. Safety and Efficacy
  • 10.3.7. Product Profile
• 10.4. BOTOX (onabotulinumtoxin A): AbbVie (Allergan)
  • 10.4.1. Product Description
  • 10.4.2. Regulatory Milestones
  • 10.4.3. Other Development Activities
  • 10.4.4. Clinical Development
  • 10.4.5. Clinical Trials Information
  • 10.4.6. Safety and Efficacy
  • 10.4.7. Product Profile
• 10.5. XEOMIN (incobotulinumtoxin A): Merz Pharmaceutical/Teijin Pharma
  • 10.5.1. Product Description
  • 10.5.2. Regulatory Milestones
  • 10.5.3. Clinical Development
  • 10.5.4. Clinical Trials Information
  • 10.5.5. Safety and Efficacy
  • 10.5.6. Product Profile
• 10.6. MYOBLOC/NERBLOC (rimabotulinumtoxinB): Supernus Pharmaceuticals/Eisai
  • 10.6.1. Product Description
  • 10.6.2. Regulatory Milestones
  • 10.6.3. Other Development Activities
  • 10.6.4. Clinical Development
  • 10.6.5. Clinical Trials Information
  • 10.6.6. Safety and Efficacy
  • 10.6.7. Product Profile

11. Emerging Drugs

• 11.1. ABP-450 (prabotulinumtoxinA): AEON Biopharma
  • 11.1.1. Drug Description
  • 11.1.2. Regulatory Milestone
  • 11.1.3. Other Development Activities
  • 11.1.4. Clinical Development
  • 11.1.5. Clinical Trials Information
  • 11.1.6. Safety and Efficacy
  • 11.1.7. Product Profile
  • 11.1.8. Analysts' Views

12. Cervical Dystonia: Market Analysis

• 12.1. Key Findings
• 12.2. Key Market Forecast Assumptions
• 12.3. Market Outlook
• 12.4. Total Market Size of Cervical Dystonia in the 7MM
• 12.5. Total Market Size of Cervical Dystonia by Therapies in the 7MM
• 12.6. Market Size of Cervical Dystonia in the US
  • 12.6.1. Total Market Size of Cervical Dystonia in the US
  • 12.6.2. The Market Size of Cervical Dystonia by Therapies in the US
• 12.7. Market Size of Cervical Dystonia in EU4 and the UK
  • 12.7.1. Total Market Size of Cervical Dystonia in EU4 and the UK
  • 12.7.2. The Market Size of Cervical Dystonia by Therapies in EU4 and the UK
• 12.8. Market Size of Cervical Dystonia in Japan
  • 12.8.1. Total Market Size of Cervical Dystonia in Japan
  • 12.8.2. The Market Size of Cervical Dystonia by Therapies in Japan

13. Key Opinion Leaders' Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

• 16.1. The United States
  • 16.1.1. Center for Medicare & Medicaid Services (CMS)
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. The United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Acronyms and Abbreviations
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight